MedTrace Logo

Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02

NCT01093664 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-10-19

No results posted yet for this study

Summary

This is a phase IB follow-up study to assess a boost immunization with AFFITOPE AD02 with regard to safety/tolerability, immunological and clinical activity in Alzheimer patients who have received the vaccine within the clinical study AFF002.

Conditions

Interventions

BIOLOGICAL

AFFITOPE AD02

s.c. injection

Sponsors & Collaborators

  • Affiris AG

    lead INDUSTRY

Principal Investigators

  • Margot Schmitz, Univ. Doz. · Ordination Schmitz

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01093664 on ClinicalTrials.gov